Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
Total Valuation
GeneDx Holdings has a market cap or net worth of $3.34B. The enterprise value is $2.73B.
Market Cap$3.34B
Enterprise Value$2.73B
Share Statistics
GeneDx Holdings has 28,726,248 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,726,248
Owned by Insiders60.46%
Owned by Institutions0.40%
Financial Efficiency
GeneDx Holdings’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -6.27%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-6.27%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee305.45K
Profits Per Employee-52.29K
Employee Count1,000
Asset Turnover0.73
Inventory Turnover10.43
Valuation Ratios
The current PE Ratio of GeneDx Holdings is 6583.4. GeneDx Holdings’s PEG ratio is ―.
PE Ratio6583.4
PS Ratio0.00
PB Ratio0.00
Price to Fair Value8.43
Price to FCF0.00
Price to Operating Cash Flow-1.42K
PEG Ratio―
Income Statement
In the last 12 months, GeneDx Holdings had revenue of 305.45M and earned -52.29M in profits. Earnings per share was -1.94.
Revenue305.45M
Gross Profit194.40M
Operating Income-23.21M
Pretax Income-52.63M
Net Income-52.29M
EBITDA-27.64M
Earnings Per Share (EPS)-1.94
Cash Flow
In the last 12 months, operating cash flow was -18.33M and capital expenditures -11.50M, giving a free cash flow of -29.83M billion.
Operating Cash Flow-18.33M
Free Cash Flow-29.83M
Free Cash Flow per Share-1.04
Dividends & Yields
GeneDx Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change273.61%
50-Day Moving Average87.01
200-Day Moving Average82.76
Relative Strength Index (RSI)78.99
Average Volume (3m)863.70K
Important Dates
GeneDx Holdings upcoming earnings date is Nov 17, 2025, After Close (Confirmed).
Last Earnings DateJul 29, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date―
Financial Position
GeneDx Holdings as a current ratio of 3.61, with Debt / Equity ratio of 44.61%
Current Ratio3.61
Quick Ratio3.42
Debt to Market Cap0.03
Net Debt to EBITDA-1.12
Interest Coverage Ratio-7.66
Taxes
In the past 12 months, GeneDx Holdings has paid -343.00K in taxes.
Income Tax-343.00K
Effective Tax Rate<0.01
Enterprise Valuation
GeneDx Holdings EV to EBITDA ratio is -75.89, with an EV/FCF ratio of -61.72.
EV to Sales6.87
EV to EBITDA-75.89
EV to Free Cash Flow-61.72
EV to Operating Cash Flow-73.62
Balance Sheet
GeneDx Holdings has $134.56M in cash and marketable securities with $62.70M in debt, giving a net cash position of -$71.86M billion.
Cash & Marketable Securities$134.56M
Total Debt$62.70M
Net Cash-$71.86M
Net Cash Per Share-$2.50
Tangible Book Value Per Share$3.22
Margins
Gross margin is 63.93%, with operating margin of -7.60%, and net profit margin of -17.12%.
Gross Margin63.93%
Operating Margin-7.60%
Pretax Margin-17.23%
Net Profit Margin-17.12%
EBITDA Margin-9.05%
EBIT Margin-16.24%
Analyst Forecast
The average price target for GeneDx Holdings is $114.14, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$114.14
Price Target Upside-7.11% Downside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast48.70%
EPS Growth Forecast―